Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-21T19:14:37.551Z Has data issue: false hasContentIssue false

Flavonoids and intestinal cancers

Published online by Cambridge University Press:  01 May 2008

Roberto Pierini
Affiliation:
Institute of Food Research, Norwich Research Park, Colney, NorwichNR4 7UA, UK
Jennifer M. Gee
Affiliation:
Institute of Food Research, Norwich Research Park, Colney, NorwichNR4 7UA, UK
Nigel J. Belshaw
Affiliation:
Institute of Food Research, Norwich Research Park, Colney, NorwichNR4 7UA, UK
Ian T. Johnson*
Affiliation:
Institute of Food Research, Norwich Research Park, Colney, NorwichNR4 7UA, UK
*
*Corresponding author: Dr Ian T. Johnson, fax +44 1603 255288, email ian.johnson@bbsrc.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Cancers of the gastrointestinal tract are amongst the most common causes of death from cancer, but there is substantial variation in incidence across populations. This is consistent with a major causative role for diet. There is convincing evidence that fruits and vegetables protect against cancers of the upper alimentary tract and the large bowel, and this has focused attention on biologically active phytochemicals, and on flavonoids in particular. Many flavonoids exert anticarcinogenic effects in vitro and in animals, and many of these effects occur via signalling pathways known to be important in the pathogenesis of colorectal, gastric and oesophageal cancers. However dietary flavonoid intakes are generally low and their metabolism in humans is extremely complex. The advent of new post-genomic technologies will do much to address these problems by making it possible to monitor patterns of gene expression in humans to provide essential molecular biomarkers of early disease. By combining such data with knowledge of the dietary exposure and bioavailability of the most effective compounds it will be possible to predict the most effective dietary sources and to properly evaluate the potential role of flavonoids in clinical nutrition.

Type
Full Papers
Copyright
Copyright © The Authors 2008

Neoplasms of the alimentary tract are amongst the most common of all cancers, but they show striking variability in incidence, both across geographical boundaries, and within populations undergoing social and environmental changes(Reference Parkin, Bray, Ferlay and Pisani1). In its review of diet and cancer published in 1997. The World Cancer Research(2) found “convincing” evidence for protective effects of fruits and vegetables against cancers of the upper aerophagic tract, stomach and lung, and of vegetables against cancers of the colon and rectum, and there is a continuing consensus in favour of a protective role for fruits and vegetables against cancers of the alimentary tract. This review is concerned with the hypothesis that one particular class of phytochemicals, the flavonoids, exert protective effects against these cancers. Flavonoids occur very widely in plants used as human foods(Reference Hollman and Arts3), and much of the colour, flavour and aroma of chocolate, tea, coffee and wine reflects the complex variety of phenolic compounds that they contain. Most of our current knowledge about these compounds has been obtained through the use of classical cell biology and biochemistry methods, but there is now increasing interest in the use of nutrigenomics to deepen our understanding of these and other phytochemicals(Reference Corthesy-Theulaz, den Dunnen, Ferre, Geurts, Muller, van Belzen and van Ommen4Reference Fuchs, Winkelmann, Johnson, Mariman, Wenzel and Daniel7), and one important goal of this review is to explore the potential for using this approach to explore the anticarcinogenic effects of flavonoids in the gut.

Flavonoids as anticarcinogens

Flavonoids are amongst the most thoroughly studied anticarcinogens, but much of the evidence has been derived from in vitro studies, using compounds such as quercetin aglycone, which is rarely found in the diet, and never in the human body. Under physiological conditions, a relatively small fraction of the quercetin glycosides found in foods is hydrolysed at the intestinal surface, and the released aglycone is absorbed and rapidly metabolised, largely to glucuronides, which are then transferred to the circulation(Reference Day, Gee, DuPont, Johnson and Williamson8). Unabsorbed polyphenols eventually become available for bacterial fermentation, yielding a mixture of phenolic acids in the colon(Reference Scalbert, Morand, Manach and Remesy9). This section is a general overview of interactions between flavonoids and potentially anticarcinogenic mechanisms.

Modulation of carcinogen metabolism

The first lines of defence against food- and air-borne carcinogens and toxins are the phase I and phase II metabolic enzymes expressed in the gut, liver and lung. Phase I metabolism involves oxidation, reduction and hydrolysis, principally via the cytochrome P450 enzymes(Reference Nelson, Kamataki, Waxman, Guengerich, Estabrook, Feyereisen, Gonzalez, Coon, Gunsalus and Gotoh10). The reaction products are often highly reactive genotoxins that form substrates for phase II enzymes such as glutathione S-transferase (GST), NAD:quinone reductase and γ-glutamylcysteine synthetase. Phase II products are water-soluble, less reactive conjugates, which are readily excreted via the kidneys or in bile. Phase I and II enzymes are inducible by compounds that interact with the xenobiotic response element (XRE) and the antioxidant response element (ARE) respectively. Those that interact primarily with the ARE, and hence selectively induce phase II enzymes without simultaneously inducing phase I activity, are often potent anticarcinogens(Reference Prochaska and Talalay11). Amongst the flavonoids, the most actively investigated are the flavanols, including epigallocatechin gallate (EGCG), the putative principal anticarcinogenic component of green tea(Reference Chou, Chu, Hsu, Chiang and Wang12).

Modulation of inflammatory pathways

Inflammation is a risk-factor for many types of cancer, and it is well established that chronic use of anti-inflammatory drugs such as aspirin reduces the risk of cancers of the colon(Reference Chan, Giovannucci, Meyerhardt, Schernhammer, Curhan and Fuchs13) and oesophagus(Reference Ranka, Gee, Johnson, Skinner, Hart and Rhodes14, Reference Vaughan, Dong, Blount, Ayub, Odze, Sanchez, Rabinovitch and Reid15). This has established that cancers of the gastrointestinal tract are susceptible to chemoprevention, and prompted a search for natural food-borne anti-inflammatory factors. One important focus of interest is compounds that interact with nuclear transcription factor κB (NF-κB). In its inactive form NF-κB is present in the cytoplasm as a complex with IκB. Activation of NF-κB is brought about by IκB kinase (IKK)-dependent phosphorylation, ubiquitination and proteolysis of IκB, which frees NF-κB to enter the nucleus and bind to the κB sequence motif in DNA. NF-κB is involved in the regulation of a large number of genes but is particularly important as an up-regulator of the inflammatory response. Phenolic substances found in plant foods and beverages inhibit NF-κB activation at various stages. Curcumin for example suppresses TNF-induced activation of IKK(Reference Singh and Aggarwal16), whereas caffeic acid phenethyl ester specifically prevents binding of NF-κB to its target DNA sequence(Reference Natarajan, Singh, Burke, Grunberger and Aggarwal17).

Another important pro-inflammatory mechanism potentially susceptible to modulation by flavonoids is that mediated by cyclooxygenase (prostaglandin H synthase). This enzyme system comprises two distinct isoforms; COX-1 produces prostaglandins essential to platelet aggregation and the maintenance of gastric mucosal integrity, and is constitutively expressed, whereas COX-2 is induced by tumour promoters and endogenous cytokines, and produces prostaglandins involved in inflammation. Many flavonoids have been shown to be COX-2 enzyme inhibitors(Reference Baumann, von Bruchhausen and Wurm18) and some, including apigenin, chrysin, and kaempferol, can suppress COX-2 transcription(Reference Liang, Tsai, Tsai, Lin-Shiau and Lin19).

Regulation of cell proliferation and apoptosis

One of the most important pathways involved in the regulation of cell proliferation in both gastric and colorectal epithelia is that involving the intracellular protein β-catenin(Reference Byun, Karimi, Marsh, Milovanovic, Lin and Holcombe20). In normal epithelial cells there is a relatively large and stable pool of β-catenin immobilised by interactions with cytoskeletal proteins, and a small labile pool in the cytoplasm. However in cancer cells the balance is altered in favour of the cytoplasmic pool because the regulatory mechanism for β-catenin is disrupted by various mutations or epigenetic events(Reference Gregorieff and Clevers21). Modulation of the β-catenin system occurs through the so-called canonical Wnt-signalling pathway. The Wnt proteins are cysteine-rich glycoproteins are released into the extracellular milieu where they interact either with membrane receptors of target cells(Reference Kundu, Choi and Surh22). Binding of Wnt to its membrane receptors initiates an intracellular signalling event that causes destabilisation of the β-catenin destruction complex, accumulation of β-catenin in the cytoplasm and increased levels of the β-catenin in the nucleus, where it leads to the transcription of a variety of pro-mitotic effector genes including C-myc, cyclin-D1, c-jun, COX-2. Wnt signalling plays an important role in gut formation during mammalian embryogenesis, and contributes to the maintenance of normal gut homeostasis in the adult. The common food-borne flavonoid quercetin(Reference Park, Chang, Hahm, Park, Kim and Yang23), which suppresses colorectal crypt cell proliferation in the rat in vivo (Reference Hara, Gee, Johnson, Krogdahl, Mathieson and Pryme24), has been shown to inhibit the β-catenin pathway in vitro (Reference Jaiswal, Marlow, Gupta and Narayan25, Reference Joe, Liu, Suzui, Vural, Xiao and Weinstein26).

The survival of most cancer cells depends critically upon their ability to divide continuously, and to evade apoptosis. A variety of different flavonoids have been shown to inhibit proliferation and enhance apoptosis in vitro (Reference Agullo, Gamet-Payrastre, Fernandez, Anciaux, Demigne and Remesy27Reference Kim, Kim, Na, Oh, Shin and Surh Ph29). Compounds that enhance apoptosis at biologically achievable concentrations in vivo are of great interest both as chemotherapeutic drugs, and as chemoprotective agents, particularly if they act selectively against transformed cells(Reference Musk, Stephenson, Smith, Stening, Fyfe and Johnson30). However, despite the great variety of naturally occurring compounds shown to be active in vitro, it has proven much more difficult to establish that food-borne flavonoids increase apoptosis in animals or humans.

Flavonoids and colorectal carcinoma

There is moderately good epidemiological evidence for protective effects of fruits and vegetables against colorectal cancer, and this has focused attention on the possibility that these effects might be due to the biological activity of flavonoids acting at one or more stages in the development of the disease. Most colorectal carcinomas in developed countries develop from initially benign adenomatous polyps via the adenoma-carcinoma sequence(Reference Winawer31). This step-wise pathway involves both morphological changes associated with the emergence and growth of the localised lesion, and a progressive disruption of the genome, including acquisition of somatic mutations(Reference Vogelstein, Fearon, Hamilton, Kern, Preisinger, Leppert, Nakamura, White, Smits and Bos32) and silencing of genes through changes to the epigenetic marks regulating gene expression. The most widely studied epigenetic mechanism is the hypermethylation of the cytosine residues in CpG-rich sequences (CpG-islands) located within the promoter regions of expressed genes(Reference Jubb, Bell and Quirke33). These sequences are normally unmethylated, but once methylated during the development of cancer they become progressively silenced by mechanisms involving recruitment of protein complexes, compaction of adjacent chromatin and suppressed transcription(Reference Bestor34). Cancers of the alimentary tract exhibit more aberrant methylation than cancers of the lung, ovary and bladder(Reference Esteller, Corn, Baylin and Herman35), and silencing of DNA-repair and tumour-suppressor genes makes a major contribution to the genomic dysfunction associated with colorectal carcinoma(Reference Issa36).

Although food-borne flavonoids undoubtedly modulate molecular signals involved in the development of colorectal cancer under experimental conditions, the concentrations of these compounds in food are relatively low and there is little epidemiological evidence to support a protective role against cancer for flavonoids derived from food(Reference Lin, Zhang, Wu, Willett, Fuchs and Giovannucci37). There is better evidence however that flavonoids from tea may play a protective role at the population level. Tea is an infusion prepared from the leaves of the plant Camellia sinensis and is one of the major sources of flavonoids in many western and oriental diets. The polyphenolic constituents of the tea infusion depend upon the processing of the leaves. Green tea is steamed immediately after picking to denature the polyphenol oxidases in the leaves, and hence stabilise the low molecular weight compounds, which are principally the catechins: epicatechin (EC), ( − )-epigallocatechin gallate (EGCG), ( − )-epigallocatechin (EGC) and ( − )-epicatechin-3-gallate (ECG). In contrast, black tea and Oolong tea are crushed and allowed to oxidise prior to drying. This leads to polymerisation of the polyphenols, forming high levels of theaflavins and thearubigens, with a corresponding reduction in the levels of catechins.

Black tea polyphenol consumption shows protective effects against oxidative DNA damage to the colon in animal models(Reference Lodovici, Casalini, De Filippo, Copeland, Xu, Clifford and Dolara38), and black tea significantly reduced the formation of aberrant crypt foci in a rats with preneoplastic lesions induced by azoxymethane. In the early stages GST and glutathione peroxidase (GPx) gene expression were up-regulated, suggesting that black tea effects might be mediated by antioxidative mechanisms(Reference Sengupta, Ghosh and Das39). EGCG reduces the invasive activity and growth of murine colon 26-L5 cell line in vitro, and significantly reduced lung metastasis in BALB/c mice inoculated with 26-L5 cells(Reference Ogasawara, Matsunaga and Suzuki40).

Orner et al. (Reference Orner, Dashwood, Blum, Diaz, Li and Dashwood41) used the Apc(min) mouse model to compare the anti-tumorigenic effects of green tea with those of “white” tea, a product that contains even higher levels of flavonoids. Mice treated with both types of tea had significantly lower numbers of tumours than the untreated controls, and there were significant reductions in beta-catenin and beta-catenin/Tcf-4 regulated proteins Cyclin D(Reference Parkin, Bray, Ferlay and Pisani1) and c-Jun in the apparently normal intestines of mice treated with both white tea and sulindac. Similarly, Ju et al, working with Apc(min) mice showed that treatment with EGCG reduced the high levels of nuclear beta-catenin in these mice, and inhibited aberrant gene expression(Reference Ju, Hong, Zhou, Pan, Bose, Liao, Yang, Liu, Hou, Lin, Ma, Shih, Carothers and Yang42).

A rigorous meta-analysis of epidemiological studies on the relationship between tea consumption and colorectal cancer was recently published by Sun et al. (Reference Sun, Yuan, Koh and Yu43), who identified 25 papers describing studies conducted in European, North American and Asian populations. Eight studies provided evidence for a protective effect of green tea such that the highest had an odds ratio for colon cancer of 0·82 (95 % CI 0·69–0·98) compared to the lowest consumers. There was no evidence of a protective effect against rectal cancer, nor was there evidence for a protective effect of black tea against cancer at either site. The same group has recently compared urinary metabolites of tea polyphenols with subsequent risk of colorectal during 16 years of follow-up in a cohort of 18 244 Chinese men. Subjects with higher levels of EGC and 4′-0-methyl-EGC in their urine had a significantly lower risk of colon cancer, but not of rectal cancer.

Wine is another commonly consumed beverage capable of delivering high concentrations of polyphenols to the alimentary tract. Polyphenols derived from red wine reduced colon tumour yield and oxidative DNA damage, induced in rat colon mucosa by the model carcinogen 1,2-dimethylhydrazine. Functional pathway analysis carried out on microarray gene expression data showed that wine polyphenol consumption down-regulated the inflammatory response and steroid metabolism(Reference Dolara, Luceri, Filippo, Femia, Giovannelli, Caderni, Cecchini, Silvi, Orpianesi and Cresci44).

Flavonoids and gastric carcinoma

Two distinct histological sub-types of gastric cancer have been identified: intestinal-type and diffuse-type(Reference Lauren45). Unlike colorectal cancer, the incidence of gastric cancer is in worldwide decline, with the sharpest reductions over the last few decades occurring in the industrialised world. However, whereas distal, intestinal-type gastric cancers have tended to decline in industrialised countries, the incidence of proximal cancers of the gastric cardia has increased recently(Reference Crew and Neugut46). The bacterium Helicobacter pylori is the principal known risk factor for gastric carcinogenesis(Reference Peek and Blaser47). Infection rates are inversely associated with affluence, both within and between countries, but the interaction between H. pylori and other environmental factors remains to be established.

As with colorectal cancer, a multistage sequence in the development of intestinal-type gastric carcinoma has been identified, beginning with chronic gastritis, and proceeding to mucosal atrophy, and intestinal metaplasia(Reference Correa48). The latter stage involves the development of a cellular phenotype similar to that of the intestine, which is associated with the ectopic expression of the protein CDX2, a transcription factor normally expressed by intestinal epithelial cells. The final stage of malignant transformation leads to the appearance of a discreet tumour with glandular histology. APC and K-RAS mutations do occur in some tumours, and methylation of the CpG-island of tumour-suppressor and DNA-repair genes is widely reported. Diffuse-type gastric cancers do not form discreet lesions but develop as small groups of cells distributed through the mucosal tissue. This pathway is associated specifically with mutations or epigenetic silencing of E-cadherin. H. pylori infection predisposes to both types of gastric cancer(Reference Huang, Sridhar, Chen and Hunt49), but its mechanism of action is best understood in the case of chronic gastritis-atrophy-metaplasia sequence of intestinal-type carcinogenesis. Recently Ruggiero et al. (Reference Ruggiero, Tombola, Rossi, Pancotto, Lauretti, Del Giudice and Zoratti50) reported that certain polyphenols ameliorate the adverse effects of H. pylori infection on the gastric mucosa in a mouse model, probably by exerting antitoxic activity.

As with colorectal cancer, there are numerous studies showing that a variety of flavonoids inhibit the proliferation of gastric carcinoma cells(Reference Yoshida, Sakai, Hosokawa, Marui, Matsumoto, Fujioka, Nishino and Aoike51) and induce apoptosis(Reference Yoshimizu, Otani, Saikawa, Kubota, Yoshida, Furukawa, Kumai, Kameyama, Fujii, Yano, Sato, Ito and Kitajima52) but relatively little evidence for protective effects of flavonoids at the population level. Sun et al. (Reference Sun, Yuan, Lee, Yang, Gao, Ross and Yu53) conducted a nested case–control study to explore the relationship between urinary markers of exposure to tea polyphenols and subsequent risk of gastric cancer in a cohort of over 18 000 Chinese men. There was a strong inverse association between urinary EGC and risk of gastric and oesophageal cancer (odds ratio 0·52, 95 % CI 0·28–0·97), which suggests that tea polyphenols may exert anticarcinogenic effects in this part of the gut, as well as the colon. It is less clear whether similar protective effects of polyphenols occur in populations consuming conventional Western diets. Lagiou et al. (Reference Lagiou, Samoli, Lagiou, Peterson, Tzonou, Dwyer and Trichopoulos54) examined the relationship between dietary intake of six classes of flavonoids (flavanones, flavan-3-ols, flavonols, flavones, anthocyanidins and isoflavones) and vitamin C in the aetiology of stomach cancer in a small case-control study conducted in Greece, and observed a statistically significant protective effect of flavanones. They commented that this might account for the apparently beneficial effects of fruit reported in some epidemiological studies, but given the small size of the study and the difficulty of estimating flavonoid intakes from dietary records, further research would be needed to explore this possibility.

It is worth noting that flavonoids also exert mutagenic effects in vitro and for a long period before the growth of interest in phytochemicals as anticarcinogens they were regarded as possible carcinogens. Gaspar et al. (Reference Gaspar, Laires, Monteiro, Laureano, Ramos and Rueff55) used the Ames test to show that the mutagenicity of red wines correlated well with their quercetin content, but it has not since been established that these adverse effects are directly relevant to human health.

Flavonoids and oesophageal carcinoma

Oesophageal cancer occurs in two histological subtypes, squamous cell carcinoma (OSCC), and adenocarcinoma (OA). Overall the disease occurs somewhat more frequently in less developed countries than in the industrialised west(Reference Ferlay, Bray, Pisani and Parkin56) but some of the steepest contrasts in reported incidence occur within countries in Africa and Asia, where squamous carcinoma is the predominant form. Such variations appear to be associated with a combination of micronutrient deficiencies and high exposure to environmental mutagens(Reference Roth, Strickland, Wang, Rothman, Greenberg and Dawsey57). Over the last 30 years, the incidence of OSCC has decreased in many industrialised countries, whereas an unexplained increase in the rates of OA has occurred in the United States and Western Europe(Reference Newnham, Quinn, Babb, Kang and Majeed58).

Typically, adenocarcinoma develops from Barrett's oesophagus, an intestinal-type metaplasia that replaces the normal squamous mucosa in the lower third of the oesophagus(Reference Prach, MacDonald, Hopwood and Johnston59), apparently in response to chronic irritation by gastric reflux. In 10–15 % of cases there is progression via low- and high-grade dysplasia to adenocarcinoma, accompanied by somatic mutations of genes including p53 and K-RAS, chromosomal losses and aneuploidy, and methylation of the CpG-islands of APC, CDKN2A, ESR1 and E-Cadherin (Reference Wild and Hardie60).

Gastro-oesophageal reflux disease (GERD) is the strongest identified risk-factor for OA(Reference Lagergren, Bergstrom, Lindgren and Nyren61), and the disease shows a strong positive relationship with obesity(Reference Lagergren, Bergstrom and Nyren62). Several epidemiological studies show evidence for an inverse correlation between fruit and vegetable consumption and risk of both OA and OSCC(Reference Bosetti, La Vecchia, Talamini, Simonato, Zambon, Negri, Trichopoulos, Lagiou, Bardini and Franceschi63, Reference Zhao, Cao, Ma and Liu64). Engel and colleagues estimated that the population attributable risk (PAR) associated with low fruit and vegetable consumption was of 29 % for OSCC and 15 % for OA(Reference Engel, Chow, Vaughan, Gammon, Risch, Stanford, Schoenberg, Mayne, Dubrow, Rotterdam, West, Blaser, Blot, Gail and Fraumeni65).

Aspirin and other synthetic COX-2 enzyme inhibitors are protective against OA(Reference Vaughan, Dong, Blount, Ayub, Odze, Sanchez, Rabinovitch and Reid15). A number of flavonoids are COX-2 inhibitors(Reference Baumann, von Bruchhausen and Wurm18) and some (e.g. apigenin, chrysin, and kaempferol) can suppress COX-2 transcription by mechanisms that include activation of the peroxisome proliferator-activated receptor (PPAR) gamma transcription factor(Reference Liang, Tsai, Tsai, Lin-Shiau and Lin19), and inhibition of NF-κB expression(Reference Liang, Huang, Tsai, Lin-Shiau, Chen and Lin66). COX-2 transcription is inhibited in vitro not just by quercetin aglycone, but also by the metabolites quercetin 3-glucuronide, quercetin 3′-sulphate, and 3′-methylquercetin 3-glucuronide. These compounds are found in human plasma, and both quercetin and quercetin 3′-sulphate also inhibit COX-2 enzyme activity(Reference O'Leary, de Pascual-Tereasa, Needs, Bao, O'Brien and Williamson67). Quercetin aglycone inhibits COX-2 expression and induces apoptosis in the oesophageal adenocarcinoma cell line OE33 in vitro (Reference Cheong, Ivory, Doleman, Parker, Rhodes and Johnson68).

EGCG is another flavonoid which is of particular interest in the context or oesophageal cancer. In studies carried out on N-nitrosomethylbenzylamine (NMBA)-induced OSCC in rats, EGCG reduced the incidence of tumours in a dose-dependent manner, and significantly down-regulated the gene expression of both cyclin D1 and COX-2(Reference Li, Shimada, Sato, Maeda, Itami, Kaganoi, Komoto, Kawabe and Imamura69). Perhaps the most intriguing property of EGCG in this context is its ability to inhibit DNA methyltransferase (DNMT) activity. Epigenetic silencing of genes involved in cell cycle regulation, like p16 and retinoic acid receptor beta (RARβ), and DNA repair, like O6-methylguanine-DNA methyltransferase (MGMT) and human mutL homologue 1 (hMLH1), are important events in OSCC development(Reference Nie, Liao, Zhao, Song, Yang, Wang and Yang70). The EGCG-induced inhibition of DNMT reversed the methylation status of the promoters of these genes in an OSCC cell line leading to their re-expression(Reference Fang, Wang, Ai, Hou, Sun, Lu, Welsh and Yang71). Similar results were obtained using the same in vitro model treated with genistein, a soy-derived isoflavone(Reference Fang, Jin, Wang, Liao, Yang, Wang and Yang72). However the inhibition of DNMT1 activity by genistein was relatively weak, suggesting that it might act by a different pathway(Reference Fang, Jin, Wang, Liao, Yang, Wang and Yang72). Other flavonoids (myricetin, quercetin, hesperetin, naringenin, epigenin and luteolin) have also been shown to inhibit DNMT activity in OSCC nuclear extracts, although less efficiently than EGCG.

Flavopiridol is a synthetic flavone identical to one obtained from the Indian plant Dysoxylum binectiferum, which has attracted a great deal of attention as a possible chemotherapeutic agent for the treatment of gastrointestinal and other solid tumours. The primary action of flavopiridol is to inhibit cyclin dependent kinases (CDK) 1, 2 and 4(Reference Carlson, Dubay, Sausville, Brizuela and Worland73). Indeed it is the first pan-cyclin-dependent kinase (CDK) inhibitor to enter clinical trials. Flavopiridol has been shown to induce G1 or G2/M cell cycle arrest and apoptosis and reduce protein levels of cyclin D1 and Retinoblastoma (Rb), which are crucial regulators of G0/G1 cell cycle checkpoint, in several OA and OSCC cell lines(Reference Schrump, Matthews, Chen, Mixon and Altorki74). Promising results have also been obtained using in vivo models of OA and OSCC. Unfortunately however, flavopiridol has adverse side effects that appear to be due to its ability to act as a general suppressor of gene transcription(Reference Blagosklonny75). Some recent studies showed that flavopiridol treatment enhanced the sensitivity to radiation of OA cell lines, and xenografts in nude mice(Reference Raju, Ariga, Koto, Lu, Pickett, Valdecanas, Mason and Milas76, Reference Sato, Kajiyama, Sugano, Iwanuma and Tsurumaru77). Further investigations are needed to assess whether flavopiridol can be used safely in combination with other therapeutic agents or radiation for clinical purposes.

Conclusion

There is substantial evidence to show that flavonoids from foods and beverages exert anticarcinogenic effects in vitro against tumours derived from epithelial cells of the alimentary tract, and that they modulate molecular signalling pathways known to be involved in human disease. There is also emerging evidence that certain flavonoid-rich foods, and particularly beverages, are associated with a reduced risk of disease at the population level. However it is difficult to prove that these different observations are causally linked, partly because of the relatively low flavonoid intakes and complexity of metabolism in humans in vivo, and partly because of the lack of adequate molecular biomarkers with which to monitor the earliest stages of disease development in humans. The advent of new post-genomic technologies can do much to address these problems. Improved analytical procedures are helping to clarify both the metabolic fate of ingested flavonoids in humans(Reference Cooke, Thomasset, Boocock, Schwarz, Winterhalter, Steward, Gescher and Marczylo78), and their bioavailability(Reference Ranka, Gee, Biro, Brett, Saha, Kroon, Skinner, Hart, Cassidy, Rhodes and Johnson79). Even more importantly, by characterising the profiles of genes and proteins that are modified in target tissues during the earliest stages of disease, and determining the extent to which these patterns of gene expression can be modulated by flavonoids, the post-genomic technologies enable us to develop rigorous molecular models for the effects of these compounds on the mucosa of the alimentary tract. Finally, by combining these data with knowledge of the bioavailability of the most effective compounds and their occurrence in food, it will become possible to predict which dietary sources offer the best protection against the major gastrointestinal cancers, and to properly evaluate the potential role of flavonoids in clinical nutrition(Reference Shapiro, Singer, Halpern and Bruck80).

Acknowledgements

The publication of this paper was made possible by the financial support of the European Co-operation in the field of Scientific and Technical (COST) Research Action 926 “Impact of new technologies on the health benefits and safety of bioactive plant compounds” (2004–2008). The authors had no conflicts of interest to disclose.

References

1Parkin, DM, Bray, F, Ferlay, J & Pisani, P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55, 74108.Google Scholar
2World Cancer Research Fund (1997) Food, Nutrition and the Prevention of Cancer: a Global Perspective, pp. 216251. Washington DC: American Institute for Cancer Research.Google Scholar
3Hollman, PCH & Arts, ICW (2000) In Flavonols, flavones and flavanols - nature, occurrence and dietary burden. J Sci Food Agric 80, 10811093.Google Scholar
4Corthesy-Theulaz, I, den Dunnen, JT, Ferre, P, Geurts, JM, Muller, M, van Belzen, N & van Ommen, B (2005) Nutrigenomics: the impact of biomics technology on nutrition research. Ann Nutr Metab 49, 355365.Google Scholar
5Davis, CD & Hord, NG (2005) Nutritional “omics” technologies for elucidating the role(s) of bioactive food components in colon cancer prevention. J Nutr 135, 26942697.CrossRefGoogle ScholarPubMed
6Mariman, EC (2006) Nutrigenomics and nutrigenetics: the ‘omics’ revolution in nutritional science. Biotechnol Appl Biochem 44, 119128.CrossRefGoogle ScholarPubMed
7Fuchs, D, Winkelmann, I, Johnson, IT, Mariman, E, Wenzel, U & Daniel, H (2005) Proteomics in nutrition research: principles, technologies and applications. Br J Nutr 94, 302314.CrossRefGoogle ScholarPubMed
8Day, AJ, Gee, JM, DuPont, MS, Johnson, IT & Williamson, G (2003) Absorption of quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. Biochem Pharmacol 65, 11991206.CrossRefGoogle ScholarPubMed
9Scalbert, A, Morand, C, Manach, C & Remesy, C (2002) Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother 56, 276282.Google Scholar
10Nelson, DR, Kamataki, T, Waxman, DJ, Guengerich, FP, Estabrook, RW, Feyereisen, R, Gonzalez, FJ, Coon, MJ, Gunsalus, IC, Gotoh, O, et al. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12, 151.Google Scholar
11Prochaska, HJ & Talalay, P (1988) Regulatory mechanisms of monofunctional and bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res 48, 47764782.Google Scholar
12Chou, FP, Chu, YC, Hsu, JD, Chiang, HC & Wang, CJ (2000) Specific induction of glutathione S-transferase GSTM2 subunit expression by epigallocatechin gallate in rat liver. Biochem Pharmacol 60, 643650.Google Scholar
13Chan, AT, Giovannucci, EL, Meyerhardt, JA, Schernhammer, ES, Curhan, GC & Fuchs, CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294, 914923.Google Scholar
14Ranka, S, Gee, JM, Johnson, IT, Skinner, J, Hart, AR & Rhodes, M (2006) Non-Steroidal Anti-Inflammatory Drugs, Lower Oesophageal Sphincter-Relaxing Drugs and Oesophageal Cancer. A Case–Control Study. Digestion 74, 109115.CrossRefGoogle ScholarPubMed
15Vaughan, TL, Dong, LM, Blount, PL, Ayub, K, Odze, RD, Sanchez, CA, Rabinovitch, PS & Reid, BJ (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6, 945952.Google Scholar
16Singh, S & Aggarwal, BB (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 270, 2499525000.Google Scholar
17Natarajan, K, Singh, S, Burke, TR Jr, Grunberger, D & Aggarwal, BB (1996) Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A 93, 90909095.CrossRefGoogle ScholarPubMed
18Baumann, J, von Bruchhausen, F & Wurm, G (1980) Flavonoids and related compounds as inhibition of arachidonic acid peroxidation. Prostaglandins 20, 627639.Google Scholar
19Liang, YC, Tsai, SH, Tsai, DC, Lin-Shiau, SY & Lin, JK (2001) Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett 496, 1218.Google Scholar
20Byun, T, Karimi, M, Marsh, JL, Milovanovic, T, Lin, F & Holcombe, RF (2005) Expression of secreted Wnt antagonists in gastrointestinal tissues: potential role in stem cell homeostasis. J Clin Pathol 58, 515519.CrossRefGoogle ScholarPubMed
21Gregorieff, A & Clevers, H (2005) Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 19, 877890.Google Scholar
22Kundu, JK, Choi, K-Y & Surh, Y-J (2006) Beta-catenin-mediated sinalling: a novel molecular target for chemoprevention with anti-inflammatory substances. Biochimica et Biophysica Acta 1765, 1424.Google Scholar
23Park, CH, Chang, JY, Hahm, ER, Park, S, Kim, HK & Yang, CH (2005) Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 328, 227234.Google Scholar
24Hara, H, Gee, JM & Johnson, IT (1999) Antiproliferative effects of quercetin in the rat gastrointestinal tract. In Antiproliferative Effects of Quercetin in the Rat Gastrointestinal Tract, pp. 4953 [Krogdahl, A, Mathieson, SD and Pryme, IF, editors]. Brussels: European Commission.Google Scholar
25Jaiswal, AS, Marlow, BP, Gupta, N & Narayan, S (2002) Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21, 84148427.Google Scholar
26Joe, AK, Liu, H, Suzui, M, Vural, ME, Xiao, D & Weinstein, IB (2002) Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8, 893903.Google Scholar
27Agullo, G, Gamet-Payrastre, L, Fernandez, Y, Anciaux, N, Demigne, C & Remesy, C (1996) Comparative effects of flavonoids on the growth, viability and metabolism of a colonic adenocarcinoma cell line (HT29 cells). Cancer Lett 105, 6170.Google Scholar
28Wenzel, U, Kuntz, S, Brendel, MD & Daniel, H (2000) Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 60, 38233831.Google ScholarPubMed
29Kim, MJ, Kim, DH, Na, HK, Oh, TY, Shin, CY & Surh Ph, DPYJ (2005) Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human gastric cancer (AGS) cells. J Environ Pathol Toxicol Oncol 24, 261269.CrossRefGoogle ScholarPubMed
30Musk, SR, Stephenson, P, Smith, TK, Stening, P, Fyfe, D & Johnson, IT (1995) Selective toxicity of compounds naturally present in food toward the transformed phenotype of humancolorectal cell line HT29. Nutr Cancer 24, 289298.Google Scholar
31Winawer, SJ (1999) Natural history of colorectal cancer. Am J Med 106, 3S6S, discussion 50S-51S.CrossRefGoogle ScholarPubMed
32Vogelstein, B, Fearon, ER, Hamilton, SR, Kern, SE, Preisinger, AC, Leppert, M, Nakamura, Y, White, R, Smits, AM & Bos, JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319, 525532.CrossRefGoogle ScholarPubMed
33Jubb, AM, Bell, SM & Quirke, P (2001) Methylation and colorectal cancer. J Pathol 195, 111134.Google Scholar
34Bestor, TH (1998) Gene silencing. Methylation meets acetylation. Nature 393, 311312.Google Scholar
35Esteller, M, Corn, PG, Baylin, SB & Herman, JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61, 32253229.Google ScholarPubMed
36Issa, JP (2000) The epigenetics of colorectal cancer. Ann N Y Acad Sci 910, 140153.CrossRefGoogle ScholarPubMed
37Lin, J, Zhang, SM, Wu, K, Willett, WC, Fuchs, CS & Giovannucci, E (2006) Flavonoid intake and colorectal cancer risk in men and women. Am J Epidemiol 164, 644651.CrossRefGoogle ScholarPubMed
38Lodovici, M, Casalini, C, De Filippo, C, Copeland, E, Xu, X, Clifford, M & Dolara, P (2000) Inhibition of 1,2-dimethylhydrazine-induced oxidative DNA damage in rat colon mucosa by black tea complex polyphenols. Food Chem Toxicol 38, 10851088.Google Scholar
39Sengupta, A, Ghosh, S & Das, S (2003) Tea can protect against aberrant crypt foci formation during azoxymethane induced rat colon carcinogenesis. J Exp Clin Cancer Res 22, 185191.Google ScholarPubMed
40Ogasawara, M, Matsunaga, T & Suzuki, H (2007) Differential effects of antioxidants on the in vitro invasion, growth and lung metastasis of murine colon cancer cells. Biol Pharm Bull 30, 200204.CrossRefGoogle ScholarPubMed
41Orner, GA, Dashwood, WM, Blum, CA, Diaz, GD, Li, Q & Dashwood, RH (2003) Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 24, 263267.CrossRefGoogle ScholarPubMed
42Ju, J, Hong, J, Zhou, JN, Pan, Z, Bose, M, Liao, J, Yang, GY, Liu, YY, Hou, Z, Lin, Y, Ma, J, Shih, WJ, Carothers, AM & Yang, CS (2005) Inhibition of intestinal tumorigenesis in Apcmin/+ mice by ( − )-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 65, 1062310631.Google Scholar
43Sun, CL, Yuan, JM, Koh, WP & Yu, MC (2006) Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 27, 13011309.Google Scholar
44Dolara, P, Luceri, C, Filippo, CD, Femia, AP, Giovannelli, L, Caderni, G, Cecchini, C, Silvi, S, Orpianesi, C & Cresci, A (2005) Red wine polyphenols influence carcinogenesis, intestinal microflora, oxidative damage and gene expression profiles of colonic mucosa in F344 rats. Mutat Res 591, 237246.CrossRefGoogle ScholarPubMed
45Lauren, P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64, 3149.Google Scholar
46Crew, KD & Neugut, AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 12, 354362.Google Scholar
47Peek, RM Jr & Blaser, MJ (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2, 2837.Google Scholar
48Correa, P (1992) Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res 52, 67356740.Google Scholar
49Huang, JQ, Sridhar, S, Chen, Y & Hunt, RH (1998) Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114, 11691179.Google Scholar
50Ruggiero, P, Tombola, F, Rossi, G, Pancotto, L, Lauretti, L, Del Giudice, G & Zoratti, M (2006) Polyphenols reduce gastritis induced by Helicobacter pylori infection or VacA toxin administration in mice. Antimicrob Agents Chemother 50, 25502552.CrossRefGoogle ScholarPubMed
51Yoshida, M, Sakai, T, Hosokawa, N, Marui, N, Matsumoto, K, Fujioka, A, Nishino, H & Aoike, A (1990) The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett 260, 1013.Google Scholar
52Yoshimizu, N, Otani, Y, Saikawa, Y, Kubota, T, Yoshida, M, Furukawa, T, Kumai, K, Kameyama, K, Fujii, M, Yano, M, Sato, T, Ito, A & Kitajima, M (2004) Anti-tumour effects of nobiletin, a citrus flavonoid, on gastric cancer include: antiproliferative effects, induction of apoptosis and cell cycle deregulation. Aliment Pharmacol Ther 20, Suppl 1, 95101.Google Scholar
53Sun, CL, Yuan, JM, Lee, MJ, Yang, CS, Gao, YT, Ross, RK & Yu, MC (2002) Urinary tea polyphenols in relation to gastric and esophageal cancers: a prospective study of men in Shanghai, China. Carcinogenesis 23, 14971503.CrossRefGoogle ScholarPubMed
54Lagiou, P, Samoli, E, Lagiou, A, Peterson, J, Tzonou, A, Dwyer, J & Trichopoulos, D (2004) Flavonoids, vitamin C and adenocarcinoma of the stomach. Cancer Causes Control 15, 6772.CrossRefGoogle ScholarPubMed
55Gaspar, J, Laires, A, Monteiro, M, Laureano, O, Ramos, E & Rueff, J (1993) Quercetin and the mutagenicity of wines. Mutagenesis 8, 5155.CrossRefGoogle ScholarPubMed
56Ferlay, J, Bray, F, Pisani, P & Parkin, DM (2001) IARC Cancer Base No. 5, GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC.Google Scholar
57Roth, MJ, Strickland, KL, Wang, GQ, Rothman, N, Greenberg, A & Dawsey, SM (1998) High levels of carcinogenic polycyclic aromatic hydrocarbons present within food from Linxian, China may contribute to that region's high incidence of oesophageal cancer. Eur J Cancer 34, 757758.Google Scholar
58Newnham, A, Quinn, MJ, Babb, P, Kang, JY & Majeed, A (2003) Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971–1998. Aliment Pharmacol Ther 17, 665676.CrossRefGoogle ScholarPubMed
59Prach, AT, MacDonald, TA, Hopwood, DA & Johnston, DA (1997) Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 350, 933.CrossRefGoogle ScholarPubMed
60Wild, CP & Hardie, LJ (2003) Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3, 676684.Google Scholar
61Lagergren, J, Bergstrom, R, Lindgren, A & Nyren, O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340, 825831.CrossRefGoogle ScholarPubMed
62Lagergren, J, Bergstrom, R & Nyren, O (1999) Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130, 883890.Google Scholar
63Bosetti, C, La Vecchia, C, Talamini, R, Simonato, L, Zambon, P, Negri, E, Trichopoulos, D, Lagiou, P, Bardini, R & Franceschi, S (2000) Food groups and risk of squamous cell esophageal cancer in northern Italy. Int J Cancer 87, 289294.3.0.CO;2-9>CrossRefGoogle ScholarPubMed
64Zhao, Y, Cao, J, Ma, H & Liu, J (1997) Apoptosis induced by tea polyphenols in HL-60 cells. Cancer Lett 121, 163167.Google Scholar
65Engel, LS, Chow, WH, Vaughan, TL, Gammon, MD, Risch, HA, Stanford, JL, Schoenberg, JB, Mayne, ST, Dubrow, R, Rotterdam, H, West, AB, Blaser, M, Blot, WJ, Gail, MH & Fraumeni, JF Jr (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95, 14041413.Google Scholar
66Liang, YC, Huang, YT, Tsai, SH, Lin-Shiau, SY, Chen, CF & Lin, JK (1999) Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20, 19451952.Google Scholar
67O'Leary, KA, de Pascual-Tereasa, S, Needs, PW, Bao, YP, O'Brien, NM & Williamson, G (2004) Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res 551, 245254.Google Scholar
68Cheong, E, Ivory, K, Doleman, J, Parker, ML, Rhodes, M & Johnson, IT (2004) Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 25, 19451952.Google Scholar
69Li, ZG, Shimada, Y, Sato, F, Maeda, M, Itami, A, Kaganoi, J, Komoto, I, Kawabe, A & Imamura, M (2002) Inhibitory effects of epigallocatechin-3-gallate on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in F344 rats. Int J Oncol 21, 12751283.Google Scholar
70Nie, Y, Liao, J, Zhao, X, Song, Y, Yang, GY, Wang, LD & Yang, CS (2002) Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 23, 17131720.Google Scholar
71Fang, MZ, Wang, Y, Ai, N, Hou, Z, Sun, Y, Lu, H, Welsh, W & Yang, CS (2003) Tea polyphenol ( − )-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63, 75637570.Google Scholar
72Fang, MZ, Jin, Z, Wang, Y, Liao, J, Yang, GY, Wang, LD & Yang, CS (2005) Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol 26, 615622.Google Scholar
73Carlson, BA, Dubay, MM, Sausville, EA, Brizuela, L & Worland, PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56, 29732978.Google Scholar
74Schrump, DS, Matthews, W, Chen, GA, Mixon, A & Altorki, NK (1998) Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 4, 28852890.Google Scholar
75Blagosklonny, MV (2004) Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 3, 15371542.CrossRefGoogle ScholarPubMed
76Raju, U, Ariga, H, Koto, M, Lu, X, Pickett, J, Valdecanas, D, Mason, KA & Milas, L (2006) Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother Oncol 80, 185191.Google Scholar
77Sato, S, Kajiyama, Y, Sugano, M, Iwanuma, Y & Tsurumaru, M (2004) Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Dis Esophagus 17, 338344.Google Scholar
78Cooke, DN, Thomasset, S, Boocock, DJ, Schwarz, M, Winterhalter, P, Steward, WP, Gescher, AJ & Marczylo, TH (2006) Development of analyses by high-performance liquid chromatography and liquid chromatography/tandem mass spectrometry of bilberry (Vaccinium myrtilus) anthocyanins in human plasma and urine. J Agric Food Chem 54, 70097013.Google Scholar
79Ranka, S, Gee, JM, Biro, L, Brett, G, Saha, S, Kroon, P, Skinner, J, Hart, AR, Cassidy, A, Rhodes, M & Johnson, IT (2007) Development of a food frequency questionnaire for the assessment of quercetin and naringenin intake. Eur J Clin Nutr (Epub ahead of print 30 May 2007).Google Scholar
80Shapiro, H, Singer, P, Halpern, Z & Bruck, R (2007) Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut 56, 426436.Google Scholar